Cannabis indicated as possible risk for gum disease in young people

Young people who are heavy smokers of cannabis may be putting themselves at significant risk for periodontal disease, according to new research.

The study, published in the Feb. 6 issue of the Journal of the American Medical Association, is believed to be the first to explore whether or not smoking a substance other than tobacco – in this case, marijuana more than other cannabis products – may be a risk factor for gum disease.

After controlling for tobacco smoking, gender, socioeconomic status and infrequent trips to the dentist by one-third of the participants, the study reported a “strong association between cannabis use and periodontitis experience by age 32.”

Study participants who reported the highest use of cannabis were 1.6 times more likely to have at least one gum site with mild periodontal disease – compared to those who had never smoked cannabis.

This group’s risk of having at least one site with more severe gum disease was estimated to be more than three times higher than the group who never used the substance.

Researchers defined the group of heavy cannabis users as participants who reported an average of 41 or more occasions of substance use per year between ages 18 and 32, equivalent to smoking the substance almost once a week through that period.

But people who reported even some cannabis (fewer than 41 times a year) were more likely to have mild and severe gum disease than people who never used the drug.

“In the United States, we think about periodontal disease as being a problem after the age of 35,” said James D. Beck, Ph.D., Kenan professor of dental ecology at the University of North Carolina at Chapel Hill School of Dentistry. “These findings, that almost 30 percent of individuals at age 32 had periodontal disease, indicate that this younger group may need more attention.”

The 903 participants are part of a longitudinal study of a group of children born at Queen Mary Hospital in Dunedin, New Zealand, between 1972 and 1973. The recent study’s senior author is W. Murray Thomson, Ph.D., a professor of dental public health at the Sir John Walsh Research Institute at the University of Otago’s School of Dentistry, in Dunedin.

Study participants received dental examinations at age 26 and a similar examination at age 32, and they gave self-assessments at ages 18, 21, 26 and 32 on their cannabis use during the previous year. In an effort to control for tobacco use, participants reported their tobacco use during four periods: up to age 18, ages 18 through 21, ages 21 through 26 and ages 26 to 32.

The study suggests that the benefits of public health measures to reduce the prevalence of cannabis use may carry over to gum disease. Additionally, researchers wrote, studying a possible association between cannabis use and periodontal disease in other populations “should be a priority for periodontal epidemiological research.”

Source: University of North Carolina at Chapel Hill

Related stories:

Milestone for cannabinoid MS study
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
Weeding out the highs of medical marijuana
Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists today (Tuesday, 15 July) by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.
Claims linking health problems and the strength of cannabis may be exaggerated
Claims that a large increase in the strength of cannabis over the last decade is driving the occurrence of mental health and other problems for users are not borne out by a study of the worldwide literature, say researchers at the National Drug and Alcohol Research Centre (NDARC) and the National Drug Research Institute (NDRI), both from Australia.
Long-term cannabis users may have structural brain abnormalities
Long-term, heavy cannabis use may be associated with structural abnormalities in areas of the brain known as the hippocampus and amygdala, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Regular marijuana use increases risk of hepatitis C-related liver damage
Patients with chronic hepatitis C (HCV) infection should not use marijuana (cannabis) daily, according to a study published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. Researchers found that HCV patients who used cannabis daily were at significantly higher risk of moderate to severe liver fibrosis, or tissue scarring.
Role seen for cannabis in helping to alleviate allergic skin disease
Administering a substance found in the cannabis plant can help the body’s natural protective system alleviate an allergic skin disease (allergic contact dermatitis), an international group of researchers from Germany, Israel, Italy, Switzerland and the U.S. has found.
Cannabis could hold the key to ending multiple sclerosis misery
Researchers investigating the role of cannabinoids - chemical substances contained within cannabis – in the treatment of multiple sclerosis (MS), have found they could significantly enhance therapy, not only by reducing nerve damage and erratic nerve impulses, but perhaps even by hindering development of the condition.
Cannabis-related schizophrenia set to rise, say researchers
If cannabis causes schizophrenia - and that remains in question - then by 2010 up to 25 per cent of new cases of schizophrenia in the UK may be due to cannabis, according to a new study by Dr Matthew Hickman of the University of Bristol and colleagues, published in Addiction journal.

News discussion:

Medicine & Health news